Gradient Investments LLC Boosts Stock Holdings in AbbVie Inc. $ABBV

Gradient Investments LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 5.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 77,648 shares of the company’s stock after acquiring an additional 3,721 shares during the quarter. Gradient Investments LLC’s holdings in AbbVie were worth $19,539,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Ranch Capital Advisors Inc. grew its position in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after acquiring an additional 4,017 shares during the period. Calamos Advisors LLC raised its holdings in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after purchasing an additional 15,458 shares during the period. Bingham Private Wealth LLC bought a new stake in shares of AbbVie in the 4th quarter worth approximately $1,147,000. Axecap Investments LLC lifted its stake in AbbVie by 713.2% in the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock valued at $3,729,000 after purchasing an additional 14,313 shares during the last quarter. Finally, Legacy Edge Advisors LLC purchased a new position in AbbVie in the fourth quarter valued at approximately $1,265,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABBV shares. Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. HSBC reaffirmed a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Piper Sandler reiterated an “overweight” rating and set a $298.00 price target on shares of AbbVie in a research note on Tuesday, June 23rd. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.70.

AbbVie Trading Up 0.8%

AbbVie stock opened at $245.82 on Friday. The firm has a 50 day simple moving average of $241.96 and a 200 day simple moving average of $224.96. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm has a market capitalization of $434.31 billion, a price-to-earnings ratio of 69.44, a P/E/G ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.